Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Julianne A Hunt

Peter J Sinclair

Ramzi Farah Sweis

Florida Kallashi

Christopher Francis Thompson

Cameron James Smith

Sander G Mills

Amjad Ali

Zhijian Lu

Dooseop Kim

Yi-Heng Chen

Hong Li

Dennis M Zaller

Joung L Goulet

Gayle E Taylor

Nazia Quraishi

William H Parsons

Kathleen M Rupprecht

Jianming Bao

James B Doherty

XiaoXia Qian

Wanying Sun

Qiaolin Deng

Shouwu Miao

Petr Vachal

John E Stelmach

Guizhen Dong

Meng-Hsin Chen

Debra L Ondeyka

Liya Chen

Swaminathan R Natarajan

Kake Zhao

Luping Liu

Mark A Holmes

Xingfang Hong

David D Wisnoski

Joann M Napolitano

Adrian A Dowst

Jennifer Kowalchick

Rowena D Ruzck

Xiaoxia Qian

Rogelio L Martinez

Samantha E Adamson

Jennifer E Kowalchick

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.

CETP inhibitors derived from benzoxazole arylamides

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety. 

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a &#x2014;CH&#x2014;.

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

SRC kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

Growing community of inventors

Scotch Plains, NJ, United States of America

Julianne A Hunt